FreeOx Biotech obtains the licence for the new neuroprotective molecule Ox-02
FreeOx Biotech has signed an exclusive licence agreement to develop and exploit the product patent of the molecule Ox-02 with the Hospital Clinic Barcelona, the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Spanish National Research Council...
FreeOx acquires the patent for the drug Ox-01 in the US for ischaemic stroke
FreeOx Biotech has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use of Ox-01 until 2038 for patients with ischaemic stroke treated with mechanical thrombectomy. “This grant...
Dr. Ángel Chamorro: “La meitat dels pacients que pateixen un ictus tornen a fer vida normal”
En motiu del Dia Mundial de l'Ictus, el programa La nit dels ignorants de Catalunya Ràdio ha entrevistat el Dr. Ángel Chamorro, un dels principals especialistes en l'ictus, director de la Unitat Funcional de Patologia Vascular Cerebral de l'Hospital Clínic de...
Dr. Ángel Chamorro: “Estamos disminuyendo las consecuencias del ictus, pero los nuevos casos crecen”
Entrevista del Dr. Ángel Chamorro en Misderechos.club en la cual explica los síntomas, factores de riesgo e incidencia del ictus, una patología que afecta a 17 millones de personas en todo el mundo. El Dr. Chamorro es neurólogo, director de la Unidad Funcional de...
FreeOx and AEC Partners sign agreement to bring new stroke drugs to market
FreeOx Biotech has taken on AEC Partners as a strategic partner in the company to accelerate development and marketing of its drug to treat brain ischemia. The priority drug is Ox-01, which is about to begin phase-III clinical trials. AEC Partners analysed the brand...
FreeOx closes €500,000 round to accelerate drugs that slow stroke
FreeOx Biotech has closed its first round of funding with €500,000 from private investors Montserrat Esteve and Francisco Javier Alsina. Created as a spin-out of Hospital Clinic Barcelona-IDIBAPS in 2017 to develop a new class of neuroprotective drugs, FreeOx has two...
FreeOx receives recognition from EIT Health
FreeOx Biotech has been selected for two first level programmes of EIT Health, a network of more than 140 member universities and companies which innovate in healthcare supported by the European Institute of Innovation and Technology (EIT) of the European Commission....
Innovative solution against the dreaded stroke
In an interview published in the Catalan newspaper "La vanguardia", Carlos Lurigados and Ángel Chamorro, CEO and Scientific Advisor of FreeOx Biotech respectively, talk about the creation of the company in 2007 as a spinout of the Hospital Clínic, of the recent...
FreeOx opens €500,000 round of investment
FreeOx Biotech has opened a round of investment hoping to raise €500,000 by June. The company’s goal this year is to accelerate development and the regulatory process for its drug candidate Ox-01, which has completed phase IIb, and begin preclinical trials with Ox-02....
FreeOx Biotech takes on Xavier Luria as strategic partner
FreeOx Biotech has taken on Xavier Luria as its new partner and strategy advisor in a bid to accelerate development and the regulatory process for its main drug candidate, Ox-01, to treat stroke. Luria is a world-renowned expert in clinical and regulatory drug...
